Psychemedics Corporation
PMD · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | 0.18 | -0.25 | 0.24 |
| FCF Yield | 7.52% | 2.06% | 0.59% | -2.95% |
| EV / EBITDA | 22.18 | -23.18 | -60.02 | -802.56 |
| Quality | ||||
| ROIC | 3.15% | -7.48% | -10.88% | -8.28% |
| Gross Margin | 31.37% | 39.40% | 32.83% | 39.61% |
| Cash Conversion Ratio | 5.39 | -0.49 | -0.15 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.95% | -7.95% | -7.34% | -5.64% |
| Free Cash Flow Growth | 254.64% | 245.68% | 116.84% | -172.11% |
| Safety | ||||
| Net Debt / EBITDA | -0.43 | -0.29 | -1.85 | -25.67 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 37.64 | 29.56 | 39.76 | 33.99 |